Product categories
Nuclear Medicine
PYROPHOSPHATE
Name:
Pyrophosphate Radiofarma® TC
Active Principle:
Sodium Pyrophosphate Decahydrate
Therapeutic Action:
It is indicated for performing bone scintigraphy, detection of cardiac pathologies and “in vivo” and “in vitro” marking of erythrocytes.
1) In vivo, in vitro or in vivo/in vitro marking of red blood cells to perform blood pool scintigraphy with the following indications in Angiocardial scintigraphy:
-Evaluation of the necrotic process of the myocardium.
-Evaluation of the ventricular ejection fraction.
-Evaluation of motility of the global and regional cardiac wall Myocardial phase imaging Imaging of organ perfusion and vascular anomalies Diagnosis and localization of occult gastrointestinal bleeding.
2) Determination of blood volume.
3) Splenic scintigraphy.
4) Evaluation of distribution of organ involvement in different types of amyloidosis.
5) Evaluation of muscle necrosis in the extremities.
6) Bone scintigraphy: evaluation of oncological and non-oncological bone abnormalities.
Nuclear Medicine
PYROPHOSPHATE
Name:
Pyrophosphate Radiofarma® TC
Active Principle:
Sodium Pyrophosphate Decahydrate
Therapeutic Action:
It is indicated for performing bone scintigraphy, detection of cardiac pathologies and “in vivo” and “in vitro” marking of erythrocytes.
1) In vivo, in vitro or in vivo/in vitro marking of red blood cells to perform blood pool scintigraphy with the following indications in Angiocardial scintigraphy:
-Evaluation of the necrotic process of the myocardium.
-Evaluation of the ventricular ejection fraction.
-Evaluation of motility of the global and regional cardiac wall Myocardial phase imaging Imaging of organ perfusion and vascular anomalies Diagnosis and localization of occult gastrointestinal bleeding.
2) Determination of blood volume.
3) Splenic scintigraphy.
4) Evaluation of distribution of organ involvement in different types of amyloidosis.
5) Evaluation of muscle necrosis in the extremities.
6) Bone scintigraphy: evaluation of oncological and non-oncological bone abnormalities.
